DEVELOPMENT AND CHARACTERIZATION OF GEMCITABINE HCI COLON TARGETED LOADED POLYMERIC NANOPARTICLE TO TARGET COLORECTAL CANCER FOLLOWED BY ORAL ADMINISTRATION.
ABSTRACT Title: Development and characterization of Gemcitabine Hcl colon targeted loaded polymeric nanoparticles to target colorectal cancer followed by oral administration. The present invention belongs to the fields of pharmaceutical technology, dosage form design and pharmacology. The present invention provides a novel approach of treating ulcerative colitis (such as solid cancer) through oral route by developing an optimal polymeric nanoparticle containing a solid pharmaceuticaly active principle. The GPNP was prepared by High Pressure Homogenization (HPH) method exploring the risk assessment technique. Optimized formulation with Eudragit S100 and Pluronic F-127 was formulated with sufficient control over size, size distribution, morphology and control led- release properties. Nanoparticles of the range 150 to 500 nm are obtained, non-cilio toxic and are found suitable for controlled delivery active pharmaceutical.
